


## Supplementary File S1

**Supplementary Figure S1.** Number of questionnaires completed per participant. Histograms with boxplots (minimum, interquartile range, median, maximum and outliers: indicated by dots) of number of questionnaires that were filled out during the study by male and female patients.



**Supplementary Table S1.** Differences in percentage of reported ADRs calculated for each sex.

Similarly reported ADRs (PT)	Male (%)	Female (%)	Absolute difference	P-value
Therapeutic product effect decreased	5.2	3.7	1.5	0.574
Sinusitis	0.9	2.8	1.9	0.445
Rhinorrhoea	0.0	1.6	1.6	0.310
Rheumatoid arthritis	0.0	2.4	2.4	0.183
Respiratory tract irritation	0.0	1.6	1.6	0.310
Respiratory tract infection	0.9	3.7	2.8	0.230
Rash pruritic	0.0	1.6	1.6	0.310
Pyrexia	0.9	3.3	2.4	0.259
Psoriasis	0.9	2.0	1.1	0.420
Pruritus	7.8	4.9	2.9	0.335
Pneumonia	3.4	5.7	2.3	0.445
Pain in extremity	3.4	2.0	1.4	0.476
Nausea	1.7	4.9	3.2	0.241
Nasopharyngitis	6.0	6.5	0.5	1.000
Injection site rash	0.0	1.6	1.6	0.310
Injection site pruritus	3.4	13.0	9.6	<b>0.004**</b>
Injection site pain	16.4	17.1	0.7	1.000
Injection site irritation	3.4	0.9	2.5	0.086
Injection site inflammation	1.7	7.3	5.6	<b>0.028*</b>
Injection site haematoma	0.9	6.9	6.0	<b>0.017*</b>
Injection site erythema	2.6	8.9	6.3	<b>0.026*</b>
Influenza like illness	2.6	3.7	1.1	0.759
Infection susceptibility increased	3.4	3.3	0.1	1.000
Hyperhidrosis	0.0	1.6	1.6	0.310
Hot flush	0.0	2.0	2.0	0.181
Herpes zoster	0.0	2.0	2.0	0.181
Headache	3.4	5.3	1.9	0.597
Haematoma	0.0	4.9	4.9	<b>0.011*</b>
Fatigue	7.8	8.5	0.7	1.000
Eye inflammation	0.9	2.4	1.5	0.437
Erythema	0.0	1.6	1.6	0.310
Eczema	2.6	1.6	1.0	0.685
Dyspnoea	1.7	2.4	0.7	1.000
Dizziness	0.9	1.6	0.7	1.000
Diarrhoea	1.7	3.3	1.6	0.512
Cystitis	0.9	5.7	4.7	<b>0.044*</b>
Cough	3.4	4.1	0.7	1.000
Arthralgia	7.8	4.5	3.3	0.222
Aphthous ulcer	0.9	1.6	0.7	1.000
Alopecia	2.6	2.4	0.2	1.000

P-values are the result of Fisher exact test before correction for multiple testing. OR=odds ratio, CI= confidence interval. PT= Preferred Term MedDRA. \*p-values <0.05. \*\*p-value <0.01.

**Supplementary Table S2.** Sex differences in burden.

	Male (n)	Female (n)	P
Arthralgia	8	10	0.052
Cough	4	10	0.252
Fatigue	9	21	0.245
Headache	4	13	0.469
Infection susceptibility increased	4	8	1.000
Injection site pain	18	42	0.116
Injection site pruritus	4	31	0.981
Nasopharyngitis	7	15	0.698
Pain in extremity	4	5	1.000
Pneumonia	4	14	0.709
Pruritus	9	12	0.944
Therapeutic product effect decreased	6	9	0.066

N= number of male and female burden values examined in the analysis.

P-values are the results of Cochran-Armitage test for trend.